PL4272834T3 - Zastosowanie terapeutyczne mitochondriów i połączonych środków mitochondrialnych - Google Patents

Zastosowanie terapeutyczne mitochondriów i połączonych środków mitochondrialnych

Info

Publication number
PL4272834T3
PL4272834T3 PL23179249.0T PL23179249T PL4272834T3 PL 4272834 T3 PL4272834 T3 PL 4272834T3 PL 23179249 T PL23179249 T PL 23179249T PL 4272834 T3 PL4272834 T3 PL 4272834T3
Authority
PL
Poland
Prior art keywords
mitochondria
agents
combined
therapeutic use
therapeutic
Prior art date
Application number
PL23179249.0T
Other languages
English (en)
Inventor
James D. MCCULLY
Sidney LEVITSKY
Douglas B. COWAN
Sitaram M. Emani
Pedro J. Del Nido
Original Assignee
The Children's Medical Center Corporation
Beth Israel Deaconess Medical Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc. filed Critical The Children's Medical Center Corporation
Publication of PL4272834T3 publication Critical patent/PL4272834T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/42—Arrangements for detecting radiation specially adapted for radiation diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/503—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Clinical applications
    • A61B8/0883—Clinical applications for diagnosis of the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
PL23179249.0T 2016-01-15 2017-01-13 Zastosowanie terapeutyczne mitochondriów i połączonych środków mitochondrialnych PL4272834T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662279489P 2016-01-15 2016-01-15
US201662279442P 2016-01-15 2016-01-15
US201662420381P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
PL4272834T3 true PL4272834T3 (pl) 2026-03-02

Family

ID=59311589

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23179249.0T PL4272834T3 (pl) 2016-01-15 2017-01-13 Zastosowanie terapeutyczne mitochondriów i połączonych środków mitochondrialnych

Country Status (14)

Country Link
US (4) US10370458B2 (pl)
EP (4) EP3735976A3 (pl)
JP (3) JP7185527B2 (pl)
CN (1) CN109152795A (pl)
AU (3) AU2017208013B2 (pl)
CA (1) CA3011472A1 (pl)
DK (1) DK4272834T3 (pl)
ES (2) ES2927427T3 (pl)
FI (1) FI4272834T3 (pl)
PL (1) PL4272834T3 (pl)
PT (1) PT4272834T (pl)
SI (1) SI4272834T1 (pl)
SM (1) SMT202500457T1 (pl)
WO (1) WO2017124037A1 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2741757B1 (en) 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
US11491480B2 (en) 2014-06-13 2022-11-08 Children's Medical Center Corporation Products and methods to isolate mitochondria
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
SI4272834T1 (sl) 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
EP3549589A4 (en) * 2016-11-30 2020-07-15 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA
KR102275822B1 (ko) * 2018-02-02 2021-07-12 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
WO2019186553A1 (en) * 2018-03-27 2019-10-03 Minovia Therapeutics Ltd. Methods for elevation of lipid and cholesterol metabolism
KR102126199B1 (ko) * 2018-04-26 2020-06-24 주식회사 파이안바이오테크놀로지 개질된 미토콘드리아 및 이의 용도
US12551504B2 (en) 2018-07-22 2026-02-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
JP2021531288A (ja) 2018-07-22 2021-11-18 ミノヴィア セラピューティクス リミテッド 眼疾患のミトコンドリア増強療法
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7458368B2 (ja) 2018-07-22 2024-03-29 ミノヴィア セラピューティクス リミテッド 筋疾患のミトコンドリア増強療法
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
EP3837359A4 (en) * 2018-08-14 2022-05-11 Imel Biotherapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DISORDERS AND HETEROPLASMIA
US12268714B2 (en) 2018-09-14 2025-04-08 Luca Science Inc. Transplantation of mitochondria into lymphoid organ and composition therefor
KR102128003B1 (ko) 2018-10-31 2020-06-29 차의과학대학교 산학협력단 분리된 미토콘드리아를 포함하는 건병증 예방 또는 치료용 약학 조성물
TWI706781B (zh) * 2019-01-30 2020-10-11 台灣粒線體應用技術股份有限公司 用於治療多發性系統退化症之醫藥組合物
JP7769545B2 (ja) * 2019-02-15 2025-11-13 チルドレンズ メディカル センター コーポレイション 心不全の治療
TWI706780B (zh) * 2019-03-27 2020-10-11 台灣粒線體應用技術股份有限公司 粒線體用於製備治療阿茲海默症之醫藥組合物的用途
US12508282B2 (en) 2019-04-03 2025-12-30 Mor Research Applications Ltd. Mitochondrial transplantation and use thereof in ocular diseases
WO2020202103A1 (en) * 2019-04-03 2020-10-08 Mor Research Applications Ltd. Mitochondrial transplantation and use thereof in ocular diseases
CN113905724A (zh) * 2019-04-15 2022-01-07 儿童医学中心公司 包含线粒体的雾化组合物及其使用方法
EP3964219A4 (en) * 2019-04-29 2022-07-06 Paean Biotechnology Inc. Pharmaceutical composition for treating sepsis or systemic inflammatory response syndrome, comprising isolated mitochondria as active ingredient
EP3962365A4 (en) * 2019-05-02 2023-02-01 Children's Medical Center Corporation PROPHYLACTIC AND THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIA
WO2020227682A1 (en) * 2019-05-08 2020-11-12 Children's Medical Center Corporation Treating cancer
EP3986425A1 (en) * 2019-06-18 2022-04-27 United Therapeutics Corporation Mitochondrial treatment of organs for transplantation
WO2021004477A1 (zh) * 2019-07-09 2021-01-14 唐凌峰 一种基于线粒体的药物递送系统及其用途
JP2022542495A (ja) * 2019-07-24 2022-10-03 ルカ・サイエンス株式会社 細胞からミトコンドリアを得る方法および得られたミトコンドリア
CN110643696B (zh) * 2019-09-10 2022-08-19 青岛大学附属医院 一种肝移植术后肝脏缺血再灌注损伤预警检测试剂盒
US12129521B2 (en) 2019-10-24 2024-10-29 Imel Biotherapeutics, Inc. Methods for detection of macro-heteroplasmy and micro-heteroplasmy in mitochondrial DNA
US12150958B2 (en) 2020-01-08 2024-11-26 The Sallie Astor Burdine Breast Foundation Compositions and methods for treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and associated methods for preparing said compositions
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途
CN111249309B (zh) * 2020-03-25 2022-08-23 复旦大学附属中山医院 一种治疗心肌缺血再灌注损伤的aldh2活化线粒体制剂及其制备方法和应用
CA3172402A1 (en) 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof
CN116096861A (zh) * 2020-04-03 2023-05-09 赛立维公司 过继性细胞转移的增强
TW202233246A (zh) * 2020-10-22 2022-09-01 南韓商白雁生物技術公司 含有抗癌劑之粒線體及其用途
KR20220062716A (ko) * 2020-11-09 2022-05-17 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 섬유증 예방 또는 치료용 약학 조성물
US20250276116A1 (en) * 2021-01-22 2025-09-04 Tufts Medical Center, Inc. Methods of mitigating myocardial damage due to extracorporeal membrane oxygenation
CN113444692A (zh) * 2021-06-29 2021-09-28 上海交通大学医学院附属第九人民医院 一种重组心肌细胞及其用途
US20240341299A1 (en) * 2021-07-23 2024-10-17 Paean Biotechnology Inc. Composition for preservation of cells, tissues or organs, comprising isolated mitochondria, and use thereof
CA3258431A1 (en) * 2022-06-10 2023-12-14 Cellvie Ag MITOCHONDRIA AS A TARGETED ADMINISTRATION PLATFORM
CA3257638A1 (en) 2022-06-10 2023-12-14 Cellvie Ag COMPOSITION AND CRYOCONSERVATION PROCESS OF MITOCHONDRIA
WO2025064863A1 (en) * 2023-09-20 2025-03-27 The Children's Medical Center Corporation Methods of vascular cell therapy and endothelial cell engraftment using mitochondria
WO2025070898A1 (ko) * 2023-09-26 2025-04-03 차의과학대학교 산학협력단 분리된 미토콘드리아를 포함하는 통증 예방 또는 치료용 조성물 및 이의 용도
WO2025090754A1 (en) * 2023-10-24 2025-05-01 The General Hospital Corporation Mitochondrial transplantation for long-term tissue preservation
WO2025126112A1 (en) * 2023-12-12 2025-06-19 Cells For Cells S.A. Composition enriched in mitochondria isolated from umbilical cord mesenchymal stem cells, useful in osteoarthritis
WO2025184537A1 (en) * 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Bio-engineered mitochondria for targeted delivery to cells
WO2025199076A1 (en) * 2024-03-18 2025-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cardiac graft function

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2561043A (en) 1946-07-12 1951-07-17 Agrashell Inc Apparatus for grinding combustible materials
US2854143A (en) 1957-02-13 1958-09-30 Ohio Commw Eng Co Centrifugal stratifier with plural filter means
US3826255A (en) 1972-06-22 1974-07-30 Hudson Oxygen Therapy Sales Co Intermittent positive pressure breathing manifold
YU41046B (en) 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
US4279890A (en) 1975-10-08 1981-07-21 Chattem, Inc. Cosmetic facial powder containing walnut shell flour
US4268460A (en) 1977-12-12 1981-05-19 Warner-Lambert Company Nebulizer
US4253468A (en) 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
DE3151275C2 (de) 1981-12-24 1986-07-10 SKF GmbH, 8720 Schweinfurt Befestigungsvorrichtung für Werkzeuge
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
DE3711054A1 (de) 1987-04-02 1988-10-13 Socop Nahrungsmittel Biophysikalisch derivatisiertes hefepraeparat, verfahren zu dessen herstellung und dieses hefepraeparat enthaltende futtermittel und pflanzenwuchsstoffe
JPH087215B2 (ja) * 1987-08-24 1996-01-29 シュティフツング・フュア・ディアグノスティッシュ・フォルシュンク 抗原および／又は抗体の検出方法および検出用の試験キット
DE4038076A1 (de) 1990-11-29 1992-06-04 Stockhausen Chem Fab Gmbh Abrasivum in kosmetischen produkten und verfahren zur herstellung und verwendung desselben
DE4139664A1 (de) 1991-12-02 1993-06-03 Diagen Inst Molekularbio Vorrichtung und verfahren zur isolierung und reinigung von nukleinsaeuren
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
US6867197B1 (en) 1995-03-30 2005-03-15 Mitokor Method of targeting conjugate molecules to mitochondria
CN1187196A (zh) 1995-06-08 1998-07-08 普罗金工业有限公司 用于提取dna的方法和装置
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20080275005A1 (en) * 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
WO2000041949A1 (en) 1999-01-18 2000-07-20 Earth Chemical Co., Ltd. Aerosol injection device
US7097832B1 (en) * 1999-03-30 2006-08-29 Myocardial Therapeutics, Inc. Intramyocardial injection of autologous bone marrow
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
US20020046410A1 (en) 2000-09-06 2002-04-18 Robert Lanza Method for generating immune-compatible cells and tissues using nuclear transfer techniques
US6562563B1 (en) * 1999-11-03 2003-05-13 Mitokor Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions
WO2003002069A2 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
WO2003012050A2 (en) * 2001-07-31 2003-02-13 Northeastern University Mitochondrial genome replenishment
US6777227B2 (en) 2002-01-09 2004-08-17 John L. Ricci Bio-reactor and cell culture surface with microgeometric surfaces
KR20100117148A (ko) 2002-04-01 2010-11-02 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US7125434B2 (en) 2002-12-19 2006-10-24 Millipore Corporation Deep gradient-density filter device
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
ATE482725T1 (de) * 2003-04-01 2010-10-15 Us Dept Of Veteran S Affaires Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen.
CN1832763A (zh) * 2003-06-05 2006-09-13 森特利昂公司 编码纤维母细胞生长因子的质粒用于治疗与高胆固醇血症或糖尿病相关的血管生成缺陷
ES2559828T3 (es) 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
US8616195B2 (en) 2003-07-18 2013-12-31 Novartis Ag Nebuliser for the production of aerosolized medication
NZ592917A (en) 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
AU2005222965B8 (en) 2004-03-15 2010-07-01 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2560415A1 (en) 2004-03-29 2005-10-13 The Procter & Gamble Company Aerosol
WO2005103229A2 (en) 2004-04-15 2005-11-03 Regents Of The University Of Minnesota Transgenomic mitochondria, transmitochondrial cells and organisms, and methods of making and using
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
JP2008512350A (ja) 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
EP1824520B1 (en) 2004-11-17 2016-04-27 Biosensors International Group, Ltd. Methods of detecting prostate cancer
WO2006059329A1 (en) 2004-12-01 2006-06-08 Hadasit Medical Research Services & Development Limited Platelet-derived microparticles for therapy
DK1853631T3 (en) * 2005-01-24 2016-03-29 Univ Texas Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
US7431222B2 (en) 2005-06-03 2008-10-07 Monterrosa Christopher H Aerosol spray masking device
WO2007011757A1 (en) 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
WO2007048046A2 (en) 2005-10-20 2007-04-26 Protiva Biotherapeutics, Inc. Sirna silencing of filovirus gene expression
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2008021484A2 (en) 2006-08-16 2008-02-21 Eutropics Pharmaceuticals Assay system to identify therapeutic agents
US7923984B2 (en) * 2007-01-19 2011-04-12 The Regents Of The University Of Michigan Universal, wireless, nano-optical voltmeters
EP2150117A4 (en) 2007-05-02 2011-10-05 Mclean Hospital Corp METHODS AND COMPOSITIONS FOR MITOCHONDRIA REPLACEMENT THERAPY
IL183818A0 (en) 2007-06-10 2007-10-31 Shimon Harpaz Uniformly abrasive confectionery product and process therefor
US20090202606A1 (en) 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
WO2009098682A2 (en) * 2008-02-04 2009-08-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for treatment of mitochondrial disorders
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
WO2010075116A2 (en) 2008-12-15 2010-07-01 Life Technologies Corporation Nucleic acid purification apparatus and method
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
AU2009336191B2 (en) 2008-12-18 2017-08-24 Novo Nordisk A/S Extended dicer substrate agents and methods for the specific inhibition of gene expression
JP5612279B2 (ja) * 2009-06-26 2014-10-22 日本合成化学工業株式会社 心筋梗塞非ヒト動物モデル及びその作製方法
US8236943B2 (en) 2009-07-01 2012-08-07 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
WO2011019807A2 (en) * 2009-08-11 2011-02-17 The Johns Hopkins University Measurement of mitochondrial membrane potential to assess organ dysfunction
CN101693884B (zh) 2009-10-21 2012-05-23 宁夏中联达生物有限公司 一种从胎盘、脐带或脂肪组织中分离提取干细胞的方法
EP2516320A4 (en) 2009-12-23 2015-03-04 Cytovera Inc SYSTEM AND METHOD FOR PARTICLE FILTRATION
US8903660B2 (en) 2010-06-24 2014-12-02 The Invention Science Fund I, Llc Rejuvenation or preservation of germ cells
US8658614B2 (en) * 2010-08-13 2014-02-25 The University of Texas Health Science Center Aptamer-containing compositions and methods for targeting E-selectin
US8846028B2 (en) * 2010-10-28 2014-09-30 The Invention Science Fund I, Llc Mitochondrial enhancement of cells
EP2654865B1 (en) 2010-12-22 2015-02-25 Koninklijke Philips N.V. Nebulizer device
US20130022666A1 (en) 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
EP2741757B1 (en) * 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
US8648034B2 (en) 2011-12-09 2014-02-11 Changhua Christian Hospital Method and applications of peptide-mediated mitochondrial delivery system
US8927268B2 (en) 2012-02-17 2015-01-06 Invent Biotechnologies, Inc. Rapid membrane isolation method for animal and plant samples
US10702556B2 (en) * 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
HUE033757T2 (en) * 2012-07-12 2017-12-28 Khondrion Ip B V Chromanyl derivatives for treating mitochondrial disease
US8895312B2 (en) * 2012-08-20 2014-11-25 The Regents Of The University Of California Nanofluidic platform for single mitochondria analysis
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
EP4357457B1 (en) 2012-10-23 2024-10-16 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
EP2928562A4 (en) 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
CN105121648B (zh) 2012-12-12 2021-05-07 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
AU2013359262C1 (en) 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014113638A1 (en) 2013-01-17 2014-07-24 Aer Devices, Inc. Multi-use albuterol maintenance therapy formulations and devices therefor
CA2848895C (en) * 2013-04-15 2021-09-07 London Health Sciences Centre Research Inc. Treatment of compartment syndrome
US9781909B2 (en) * 2013-07-17 2017-10-10 University Of Manitoba Mito-Ob: a transgenic mouse model for obesity
US10017566B2 (en) 2013-11-12 2018-07-10 The Brigham And Women's Hospital, Inc. Growth differentiation factor (GDF) for treatment of diastolic heart failure
US11491480B2 (en) 2014-06-13 2022-11-08 Children's Medical Center Corporation Products and methods to isolate mitochondria
US9912376B2 (en) 2014-07-15 2018-03-06 Adtran, Inc. Managing crosstalk in vectored transmissions
JP6441472B2 (ja) * 2014-09-30 2018-12-19 台灣粒線體應用技術股▲扮▼有限公司Ｔａｉｗａｎ Ｍｉｔｏｃｈｏｎｄｒｉｏｎ Ａｐｐｌｉｅｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． 活性成分として外因性ミトコンドリアを含む組成物、ならびにその使用およびそのための細胞修復法
CN107249600A (zh) 2014-12-31 2017-10-13 台湾粒线体应用技术股份有限公司 新颖医药组合物及其用于治疗肺损伤的用途
IL299482B2 (en) 2015-02-26 2025-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched with active mitochondria
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US11903974B2 (en) 2015-11-30 2024-02-20 Flagship Pioneering Innovations V, Inc. Methods and compositions relating to chondrisomes from cultured cells
SI4272834T1 (sl) * 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
WO2018092839A1 (ja) 2016-11-16 2018-05-24 国立大学法人北海道大学 心不全の治療及び／又は予防に用いるための心筋幹細胞の製造方法
WO2019186553A1 (en) 2018-03-27 2019-10-03 Minovia Therapeutics Ltd. Methods for elevation of lipid and cholesterol metabolism
JP7769545B2 (ja) 2019-02-15 2025-11-13 チルドレンズ メディカル センター コーポレイション 心不全の治療
CN113905724A (zh) 2019-04-15 2022-01-07 儿童医学中心公司 包含线粒体的雾化组合物及其使用方法
EP3962365A4 (en) * 2019-05-02 2023-02-01 Children's Medical Center Corporation PROPHYLACTIC AND THERAPEUTIC USE OF MITOCHONDRIA AND COMBINED MITOCHONDRIA

Also Published As

Publication number Publication date
JP2024161552A (ja) 2024-11-19
AU2023201193A1 (en) 2023-04-06
SMT202500457T1 (it) 2026-01-12
US20180057610A1 (en) 2018-03-01
EP4272834B1 (en) 2025-09-03
AU2017208013B2 (en) 2022-12-01
US20200123273A1 (en) 2020-04-23
EP3735976A3 (en) 2021-01-27
JP2023018100A (ja) 2023-02-07
PT4272834T (pt) 2025-12-10
AU2017208013A1 (en) 2018-08-09
EP4653048A3 (en) 2026-03-04
ES3057779T3 (en) 2026-03-04
JP2019507729A (ja) 2019-03-22
EP3402490A4 (en) 2019-08-07
JP7543378B2 (ja) 2024-09-02
SI4272834T1 (sl) 2026-03-31
EP3402490B1 (en) 2022-06-01
EP3735976A2 (en) 2020-11-11
CN109152795A (zh) 2019-01-04
WO2017124037A1 (en) 2017-07-20
ES2927427T3 (es) 2022-11-04
DK4272834T3 (da) 2025-12-15
FI4272834T3 (fi) 2025-12-05
EP3402490A1 (en) 2018-11-21
JP7185527B2 (ja) 2022-12-07
US20230183380A1 (en) 2023-06-15
CA3011472A1 (en) 2017-07-20
US12600800B2 (en) 2026-04-14
AU2023201193B2 (en) 2025-01-23
AU2025202775A1 (en) 2025-05-08
US10370458B2 (en) 2019-08-06
US20230416413A1 (en) 2023-12-28
EP4272834A3 (en) 2024-01-03
EP4272834A2 (en) 2023-11-08
EP4653048A2 (en) 2025-11-26
US12168700B2 (en) 2024-12-17

Similar Documents

Publication Publication Date Title
PL4272834T3 (pl) Zastosowanie terapeutyczne mitochondriów i połączonych środków mitochondrialnych
IL293377B1 (en) Hsd17b13 variants and uses thereof
HRP20260160T1 (hr) Uporaba inhibitora miostatina i kombiniranih terapija
PT3694529T (pt) Proteínas triespecíficas e métodos de utilização
DK3641819T3 (da) Anvendelse af cannabidiol i behandling af tuberøst sklerosekompleks
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
EP3526222A4 (en) TYK2 INHIBITORS AND THEIR USES
EP3528816A4 (en) TYK2 INHIBITORS AND USES THEREOF
HRP20251095T1 (hr) Neoantigeni i metode njihove uporabe
IL263030A (en) Pegylated liposomes and methods of use
HRP20260151T1 (hr) Modificirani polipeptidi i njihova uporaba
PT3548033T (pt) Compostos e respectivos métodos de utilização
IL263680A (en) Combination therapies
DK3411398T3 (da) Målrettede terapeutiske midler og anvendelse heraf
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
PL3179991T3 (pl) Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
IL283782A (en) Anellosomes and methods of use
PL4335517T3 (pl) Podawanie i dawkowanie diaminofenotiazyn
PL3512517T3 (pl) Stosowanie pridopidyny w leczeniu lęku i depresji
HUE071358T2 (hu) Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
IL258997B (en) Honey-cannabinoid therapeutic composition
IL250173B (en) Actuation mechanism and associated methods
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR